Anti-Cancer Drug Derived From Fungus Shows Promise In Clinical Trials
OXFORD, UK - A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound. Oxford University researchers have worked in collaboration with industry leaders NuCana to assess a novel
